FDA approves Vuity, first eye drop to treat presbyopia
Click Here to Manage Email Alerts
Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia.
The approval for the pilocarpine HCl ophthalmic solution 1.25% was granted Oct. 28, according to the FDA’s website.
In this exclusive video, George O. Waring IV, MD, principal investigator for the GEMINI I and GEMINI 2 phase 3 clinical studies of Vuity for the treatment of presbyopia, discusses the importance of the approval to the ophthalmic community.
“We learned that this drug has a rapid onset of almost 15 minutes and an exceptional duration, so this is a durable drug out to 6 hours relative to controls that improved distance-corrected near visual acuity almost three lines without affecting distance vision,” Waring said in the video.
Collapse
Press Release
Read more about
Click Here to Manage Email Alerts